annual accounts payable:
$235.40M-$80.11M(-25.39%)Summary
- As of today (July 1, 2025), BMRN annual accounts payable is $235.40 million, with the most recent change of -$80.11 million (-25.39%) on December 31, 2024.
- During the last 3 years, BMRN annual accounts payable has risen by +$35.73 million (+17.89%).
- BMRN annual accounts payable is now -25.39% below its all-time high of $315.51 million, reached on December 31, 2023.
Performance
BMRN Accounts payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly accounts payable:
$293.75M+$58.35M(+24.79%)Summary
- As of today (July 1, 2025), BMRN quarterly accounts payable is $293.75 million, with the most recent change of +$58.35 million (+24.79%) on March 31, 2025.
- Over the past year, BMRN quarterly accounts payable has increased by +$1.51 million (+0.52%).
- BMRN quarterly accounts payable is now -6.90% below its all-time high of $315.51 million, reached on December 31, 2023.
Performance
BMRN quarterly accounts payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
BMRN Accounts payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -25.4% | +0.5% |
| 3 y3 years | +17.9% | +56.4% |
| 5 y5 years | -2.3% | +24.9% |
BMRN Accounts payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -25.4% | +17.9% | -6.9% | +47.4% |
| 5 y | 5-year | -25.4% | +23.0% | -6.9% | +78.0% |
| alltime | all time | -25.4% | >+9999.0% | -6.9% | >+9999.0% |
BMRN Accounts payable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $293.75M(+24.8%) |
| Dec 2024 | $235.40M(-25.4%) | $235.40M(-24.6%) |
| Sep 2024 | - | $312.32M(+21.3%) |
| Jun 2024 | - | $257.41M(-11.9%) |
| Mar 2024 | - | $292.24M(-7.4%) |
| Dec 2023 | $315.51M(+36.4%) | $315.51M(+4.7%) |
| Sep 2023 | - | $301.37M(+8.4%) |
| Jun 2023 | - | $277.94M(+5.0%) |
| Mar 2023 | - | $264.78M(+14.5%) |
| Dec 2022 | $231.24M(+15.8%) | $231.24M(+11.6%) |
| Sep 2022 | - | $207.16M(+4.0%) |
| Jun 2022 | - | $199.25M(+6.1%) |
| Mar 2022 | - | $187.81M(-5.9%) |
| Dec 2021 | $199.68M(+4.3%) | $199.68M(-1.8%) |
| Sep 2021 | - | $203.32M(+15.5%) |
| Jun 2021 | - | $176.07M(+6.7%) |
| Mar 2021 | - | $165.00M(-13.8%) |
| Dec 2020 | $191.43M(-20.6%) | $191.43M(-12.2%) |
| Sep 2020 | - | $218.02M(+5.9%) |
| Jun 2020 | - | $205.87M(-12.5%) |
| Mar 2020 | - | $235.16M(-2.4%) |
| Dec 2019 | $240.98M(+16.1%) | $240.98M(+6.3%) |
| Sep 2019 | - | $226.77M(+1.3%) |
| Jun 2019 | - | $223.95M(-0.2%) |
| Mar 2019 | - | $224.38M(+8.1%) |
| Dec 2018 | $207.62M(+24.6%) | $207.62M(+17.0%) |
| Sep 2018 | - | $177.40M(+6.6%) |
| Jun 2018 | - | $166.42M(-3.4%) |
| Mar 2018 | - | $172.19M(+3.3%) |
| Dec 2017 | $166.62M(-12.9%) | $166.62M(+6.1%) |
| Sep 2017 | - | $157.02M(-0.8%) |
| Jun 2017 | - | $158.23M(+16.7%) |
| Mar 2017 | - | $135.60M(-29.1%) |
| Dec 2016 | $191.35M(+6.7%) | $191.35M(+28.6%) |
| Sep 2016 | - | $148.77M(-3.2%) |
| Jun 2016 | - | $153.65M(+0.5%) |
| Mar 2016 | - | $152.86M(-14.7%) |
| Dec 2015 | $179.29M(+28.5%) | $179.29M(+10.0%) |
| Sep 2015 | - | $162.93M(+20.0%) |
| Jun 2015 | - | $135.77M(+4.4%) |
| Mar 2015 | - | $130.07M(-6.8%) |
| Dec 2014 | $139.51M(+46.4%) | $139.51M(+20.5%) |
| Sep 2014 | - | $115.75M(+14.5%) |
| Jun 2014 | - | $101.05M(+26.8%) |
| Mar 2014 | - | $79.72M(-16.3%) |
| Dec 2013 | $95.30M(+41.9%) | $95.30M(+28.3%) |
| Sep 2013 | - | $74.30M(+8.7%) |
| Jun 2013 | - | $68.36M(-2.1%) |
| Mar 2013 | - | $69.81M(+4.0%) |
| Dec 2012 | $67.15M | $67.15M(+486.0%) |
| Sep 2012 | - | $11.46M(-8.3%) |
| Jun 2012 | - | $12.50M(+0.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2012 | - | $12.44M(-65.5%) |
| Dec 2011 | $36.09M(+628.2%) | $36.09M(+407.8%) |
| Sep 2011 | - | $7.11M(-2.0%) |
| Jun 2011 | - | $7.25M(+37.5%) |
| Mar 2011 | - | $5.27M(+6.4%) |
| Dec 2010 | $4.96M(-34.5%) | $4.96M(-31.0%) |
| Sep 2010 | - | $7.18M(-26.0%) |
| Jun 2010 | - | $9.71M(+196.3%) |
| Mar 2010 | - | $3.28M(-56.7%) |
| Dec 2009 | $7.57M(+547.3%) | $7.57M(+264.5%) |
| Sep 2009 | - | $2.08M(-93.3%) |
| Jun 2009 | - | $31.01M(+498.9%) |
| Mar 2009 | - | $5.18M(+155.2%) |
| Sep 2008 | - | $2.03M(-28.7%) |
| Jun 2008 | - | $2.85M(+22.4%) |
| Mar 2008 | - | $2.33M(+99.0%) |
| Dec 2007 | $1.17M(-48.8%) | $1.17M(-11.0%) |
| Sep 2007 | - | $1.31M(+74.1%) |
| Jun 2007 | - | $754.00K(+0.8%) |
| Mar 2007 | - | $748.00K(-67.3%) |
| Dec 2006 | $2.29M(+372.1%) | $2.29M(+52.5%) |
| Sep 2006 | - | $1.50M(+548.5%) |
| Jun 2006 | - | $231.00K(-47.5%) |
| Mar 2006 | - | $440.00K(-9.1%) |
| Dec 2005 | $484.00K(-98.2%) | $484.00K(-10.2%) |
| Sep 2005 | - | $539.00K(-76.8%) |
| Jun 2005 | - | $2.32M(-5.9%) |
| Mar 2005 | - | $2.47M(-90.9%) |
| Dec 2004 | $27.25M(+169.8%) | $27.25M(+5747.4%) |
| Sep 2004 | - | $466.00K(-44.5%) |
| Jun 2004 | - | $840.00K(-63.5%) |
| Mar 2004 | - | $2.30M(-77.2%) |
| Dec 2003 | $10.10M(+156.9%) | $10.10M(-24.6%) |
| Sep 2003 | - | $13.40M(+10.5%) |
| Jun 2003 | - | $12.12M(+27.2%) |
| Mar 2003 | - | $9.53M(+142.5%) |
| Dec 2002 | $3.93M(-8.3%) | $3.93M(+415.1%) |
| Sep 2002 | - | $763.00K(-62.1%) |
| Jun 2002 | - | $2.01M(-36.8%) |
| Mar 2002 | - | $3.19M(-25.6%) |
| Dec 2001 | $4.28M(-9.8%) | $4.28M(+9.2%) |
| Sep 2001 | - | $3.92M(+28.7%) |
| Jun 2001 | - | $3.05M(+88.7%) |
| Mar 2001 | - | $1.62M(-66.0%) |
| Dec 2000 | $4.75M(+53.4%) | $4.75M(+164.9%) |
| Sep 2000 | - | $1.79M(+81.0%) |
| Jun 2000 | - | $990.00K(-27.6%) |
| Mar 2000 | - | $1.37M(-55.8%) |
| Dec 1999 | $3.10M(+121.1%) | $3.10M(-38.1%) |
| Sep 1999 | - | $5.00M(-16.7%) |
| Jun 1999 | - | $6.00M(+650.0%) |
| Mar 1999 | - | $800.00K |
| Dec 1998 | $1.40M | - |
FAQ
- What is BioMarin Pharmaceutical annual accounts payable?
- What is the all time high annual accounts payable for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual accounts payable year-on-year change?
- What is BioMarin Pharmaceutical quarterly accounts payable?
- What is the all time high quarterly accounts payable for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly accounts payable year-on-year change?
What is BioMarin Pharmaceutical annual accounts payable?
The current annual accounts payable of BMRN is $235.40M
What is the all time high annual accounts payable for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual accounts payable is $315.51M
What is BioMarin Pharmaceutical annual accounts payable year-on-year change?
Over the past year, BMRN annual accounts payable has changed by -$80.11M (-25.39%)
What is BioMarin Pharmaceutical quarterly accounts payable?
The current quarterly accounts payable of BMRN is $293.75M
What is the all time high quarterly accounts payable for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly accounts payable is $315.51M
What is BioMarin Pharmaceutical quarterly accounts payable year-on-year change?
Over the past year, BMRN quarterly accounts payable has changed by +$1.51M (+0.52%)